Overview

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate the efficacy of TMC435 in combination with peginterferon (PegIFN) + ribavirin (RBV) by means of establishing its non- inferiority compared to an approved regimen of telaprevir + PegIFN + RBV in patients who have previously failed PegIFN.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen R&D Ireland

Treatments:

Peginterferon alfa-2a
Ribavirin
Simeprevir